Stuart H. Burri, MD

Stuart H. Burri, MD

workRadiation Oncologist
location_onRotates to multiple locations

About Dr. Burri

In my spare time I keep busy with my wife and three children. We enjoy traveling as a family and I have spent more than my fair share of time at fencing tournaments, school plays, basketball and soccer games, as well as Boy Scout camping trips.  I am active at St. John’s Episcopal Church and in the community including being past chairman for the Brain Tumor Fund for the Carolinas.

"I enjoy the cutting edge nature of radiation treatments and particularly enjoy treating patients with high-dose precise radiation treatments who historically would not have had further treatment options."

Dr. Burri

Licensure

North Carolina# 2000-00192

South Carolina #20728

Georgia #042023

Professional Organizations

ASTRO

SNO

ASCO


Awards & Affiliations


Education

Emory University School of Medicine

1996 — 2000

Atlanta, Georgia

Department of Radiation Oncology
Chief Resident: 7/98 to 12/98 & 7/99 to 6/00

Emory University School of Medicine

1995 — 1996

Atlanta, Georgia

Resident in Medicine-Preliminary

Emory University School of Medicine

1991 — 1995

Atlanta, Georgia

M.D. - Doctor of Medicine

Wake Forest University

1987 — 1991

Winston-Salem, North Carolina

B.S. in Biology and History
Magna Cum Laude, Honors in History


Employment

SERO

2000-Present

Charlotte, North Carolina


Publications

Find Dr. Burri’s full list of publications on PubMed here.


Books

  • Glioblastoma Multiforme, Jonas M. Sheehan, Robert Cavaliere, Elena Farace, Markus Bredel and Stuart H. Burri Neurology Research International, Volume 2012 (2012), Article ID 819304.

Selected Meeting Presentations

  • Poster Presentation.  The use of Glia-Site in the primary management of brain metastases results in a high rate of radiation necrosis and re-operation.  12th Annual Meeting of the Society for Neuro-Oncology. Dallas, Texas. November 2007.
  • Poster Presentation.  Neo-adjuvant pre-operative stereotactic radiosurgery in the management of brain metastases that require surgical resection.  57th Annual Meeting of the Congress of Neurological Surgeons. San Diego, California. October 2007.
  • Poster Presentation.  Pre-operative radiosurgery in the management of symptomatic brain metastases. 56th Annual Meeting of the Congress of Neurological Surgeons.  Chicago, Illinois.  October 2006.
  • Poster Presentation. Long-term follow-up of balloon-based brachytherapy (Glia-site) for treatment of high-grade gliomas and brain metastases is associated with a rising risk of radiation necrosis, but few late failures. 9th Annual Meeting of the Society for Neuro-Oncology. Toronto, Ontario. November 2004.
  • Poster Presentation. Encouraging early results using the Glia-Site brachytherapy device as a portion of initial therapy for malignant gliomas. 8th  Annual Meeting of the Society for Neuro-Oncology. Keystone, Colorado. November 2003.
  • Oral Presentation.  Black and White Patients fare equally well when treated with Post-Lumpectomy Radiotherapy.  42nd Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO).  Boston, Massachusetts. October 2000.
  • Oral Presentation.  Breast Conservation is an Effective Option in  Black, Medically Indigent Patients. 85th Annual Meeting of the Radiologic Society of North America (RSNA). Chicago, Illinois. November 1999.
  • Oral Presentation. ‘Loop” Domain Deletional Mutant of Bcl-XL  is   as effective as p29 Bcl-XL in inhibiting Radiation-Induced Cytosolic Accumulation of Cytochrome C, Caspase-3 Activity and Apoptosis.  40th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO).  Phoenix, Arizona.  October, 1998.
  • Oral Presentation Effect of Bcl-XL or its ‘Loop’ Deletional Mutant Expression on irradiation-induced Cytosolic Cytochrome c, Caspase-3 Activity and Apoptosis.  89th Annual Meeting of the American Association for Cancer Research (AACR).  New Orleans, Louisiana, 1998.

Abstracts

  • Burri, SH, Abben C, Lanning KD, Williams PA. Physician Report Card Significantly Reduces Supplemenratary Requests for Documentation, Increasing Efficiency of the Professional Billing of a Large Single Specialty Radiation Oncology Practice. International Journal of Radiation Oncology • Biology • Physics: 99(2):E549. 2017.
  • Heinzerling JH, Hampton CJ, Robinson M, Bright M, Symanowski JT, Moeller BJ, Mileham K, Burri SH, Foster RD. Use of 3D Optical Surface Mapping for Quantification of Interfraction Set up Error and Intrafraction Motion during Stereotactic Body Radiation Therapy Treatments of the Lung and Abdomen. International Journal of Radiation Oncology • Biology • Physics: 99(2):E670. 2017.
  • Prabhu RS, Press RH, Boselli DM, Patel K, Symanowski JT, Lankford SP, McCammon RJ, Moeller BJ, Heinzerling JH, Fasola C, Asher A, Sumrall AL, Curran WJ, Jr., Shu HKG, Crocker IR, Burri SH. External validity of a nomogram predicting risk of 6-month and 9-month distant brain failure after initial stereotactic radiosurgery alone for brain metastases in an independent multi-institutional patient cohort. International Journal of Radiation Oncology • Biology • Physics;99:E525-E526. 2017.
  • Press RH, Boselli DM, Patel K, Symanowski JT, Lankford SP, McCammon RJ, Moeller BJ, Heinzerling JH, Fasola C, Asher A, Sumrall AL, Curran WJ, Jr., Shu HKG, Crocker IR, Burri SH Prabhu RS. External validity of a nomogram and recursive partitioning analysis to predict for distant brain failure after stereotactic radiosurgery alone for brain metastases: Multi-institutional analysis. International Journal of Radiation Oncology • Biology • Physics;99:E101. 2017.
  • Burri SH, Kelly RP, Symanowski J, Boltes M, Ballinger W, Wait SD, Haggstrom D, Sumrall A, Prabhu RS, Asher AL. Is There a Role for Stereotactic Biopsy of Unresectable Malignant Brain Lesions? An Analysis of Short-Term Morbidity and Mortality. International Journal of Radiation Oncology • Biology • Physics;96(2):E103. 2016
  • Sumrall A, Haggstrom D, Perera S, Jennings D, Burri SH, Asher A. Using Bevacizumab to Manage Recurrent/Progressive Meningiomas: A Retrospective Analysis. Neuro-Oncology 18:S(6)vi105. 2016
  • Patel K, Burri SH, Symanowski J, Boselli D, Sumrall A, Press RH, Fraser RW, Zhong J, Olson JJ, Curran WJ, Jr., Shu HKG, Crocker IR Prabhu RS. Comparing preoperative stereotactic radiosurgery (srs) to postoperative whole-brain radiation therapy (wbrt) for resectable brain metastases: A multi-institutional analysis. International Journal of Radiation Oncology • Biology • Physics;96:E85-E86. 2016.
  • Press RH, Burri SH, Boselli D, Symanowski J, Patel K, Lankford S, McCammon RJ, Moeller BJ, Heinzerling JH, Fasola C, Asher AL, Sumrall A, Curran WJ, Jr., Shu HK, Crocker IR, Prabhu RS. External validity of a risk stratification score predicting early distant brain failure and salvage whole-brain radiation therapy after stereotactic radiosurgery for brain metastases. International Journal of Radiation Oncology • Biology • Physics;96:E122. 2016.
  • Sumrall A, Haggstrom D, Asher A, Crimaldi A, Prabhu R, Wait S,  Burri SH. Asseing the Safety of Combination Therapy with Bevacizumab and Optune for High Grade Gliomas. Neuro-Oncology 17: S(5), 1: v16. 2015.
  • Sumrall A,  Haggstrom D, Asher A,  Crimaldi A, Prabhu R, Wait S, Burri SH. Managing Recurrent Grade III Gliomas with Combination Therapy of Bevacizumab and Optune. Neuro-Oncology 17:S(5):v16. 2015.
  • Prabhu RS, Press RH, Patel KR, Lankford SP, McCammon RJ, Moeller BJ, Heinzerling JH, Fasola CE, Asher AL, Wait SD, Sumrall AL, Curran WJ, Shu H-KG, Crocker IR, Burri SH. Single fraction stereotactic radiosurgery (SRS) alone versus surgical resection and SRS boost for large brain metastases: A multi-institutional analysis. ASCO Meeting Abstracts 2016;34:2076. 2015.
  • Patel K, Asher A, Burri SH, Fraser RW, Kandula S, Press RH, Chen Z, Zhang C, Hadjipanayis CG, Olson J, Oyesiku N, Curran WJ, Jr., Shu HKG, Crocker IR, Prabhu RS. Comparing Preoperative Stereotactic Radiosurgery (SRS) to Postoperative SRS for Resectable Brain Metastases. International Journal of Radiation Oncology • Biology • Physics;93:S38-S39. BEST OF ASTRO 2015
  • Crimaldi AJ, II, Walsh J, Symanowski J, Haake MR, McHaffie DR, Sharp HJ, Moeller BJ, Thakkar VV, McCammon RJ, Prabhu RS, Mitro GC, Konefal J, Trautmann TG, Plunkett SR, Fraser RW, Burri SH. Treatment (tx) of dupuytren’s contracture (dc) and ledderhose disease (ld) with radiation therapy (rt). International Journal of Radiation Oncology • Biology • Physics;93:E467. 2015.
  • Prabhu RS, Patel KR, Burri SH, Crocker IR, Fraser RW, Zhang C, Chen Z, Kandula S, Zhong J, Press RH, Olson JJ, Oyesiku NM, Wait SD, Curran WJ, Shu HK, Asher AL. Patterns of Recurrence and Toxicity for Pre-operative versus Post-operative Stereotactic Radiosurgery (SRS) for Resected Brain Metastases: A Multi-Institutional Analysis. Congress of Neurological Surgeons Annual Meeting 2015. Section on Tumors, Neurosurgical Forum.
  • Heinzerling JH, McCammon RJ, Prabhu RS, Moeller BJ, Burri SH, Sharp HJ, McHaffie DR, Thakkar VV, Lankford SP, Butler JM, Crimaldi AJ, Haake MR, McCall BT, Mileham KF, Carrizosa DR, Haggstrom DE, Reames MK, Frenette GP, Kim ES, Fraser RW. Stereotactic Ablative Body Radiosurgery (SABR) in Early-Stage Lung Cancer: Can Results of Advanced Cancer Care in an Innovative De-Centralized Cancer Institute Replicate Favorable Clinical Trial Results? International Journal of Radiation Oncology • Biology • Physics;90:S613-S614. 2014
  • Burri SH, Sumrall AL, Kelly RP, Boltes PO, Haggstrom DE, Prabhu RS, Smith MD, Ballinger WE, Symanowski JT, Fraser RW, Asher AL. Outcomes in patients with unresected gliomablastoma including assessment of bevacizumab as a component of initial therapy. Journal of Clinical Oncology: 32:15S(I) 131s. 2014.
  • Sumrall A, Haggstrom D, Crimaldi A, Symanowski J, Giglio P, Asher A, Burri SH. Use of NovoTTF-100A in Heavily Pre-treated Patients with Relapsed High Grade Glioma : A Retrospective Chart Review. Neuro-Oncology 15(3) iii83. 2013.
  • Burri SH, Asher AL, Mueller M, Fraser RW. The use of Glia-Site in the primary management of brain metastases results in a high rate of radiation necrosis and re-operation. Neuro-Oncology 9(4):586#RT-23. 2007.
  • Sheehan J, Burri SH, Laws ER, Farace E. Delay in radiation leads to shorter length of survival in GBM:Analysis of the glioma outcomes data. Neuro-Oncology 9(4):581RT-3. 2007.
  • Burri SH, Asher AL, Mueller ML, Cagle S, Fraser RW. Neo-adjuvant pre-operative stereotactic radiosurgery in the management of brain metastases that require surgical resection. Proceeding of Congress of Neurological Surgeons 57th Annual Meeting San Diego, California October 2007.
  • Burri SH, Asher AL, Fraser RW. Pre-operative Radiosurgery in the Management of Symptomatic Brain Metastases. Proceeding of Congress of Neurological Surgeons 56th Annual Meeting Chicago, Illinois, October 2007.
  • Burri SH, Asher AL, Norton HJ, Fraser RW. Long-term follow-up of balloon-based brachytherapy (Glia-site) for treatment of high-grade gliomas and brain metastases is associated with a rising risk of radiation necrosis, but few late failures. Neuro-Oncology 6(4):359#RT-03. 2004.
  • Gabayan AJ, Sanan A, Bastin K, Burri SH, Green S, Jenrette J, Lustig R, Papagikos M, Patel A, Schultz C, Watson G, Stea B. Glia-Site radiation therapy system for the treatment of recurrent malignant glioma: A multi-institutional analysis. International Journal of Radiation Oncology Biology Physics 60:1S 258#1002. 2004.
  • Gabayan AJ, Sanan A, Bastin K, Burri SH, Green S, Jenrette J, Lustig R, Papagikos M, Patel A, Schultz C, Watson G, Stea B. Glia-Site radiation therapy system for the treatment of recurrent malignant glioma: A multi-institutional analysis.  Radiotherapy and Oncology 71(2):S62. 2004.
  • Burri SH, Sills AK, Fraser RW, Asher AL. Encouraging early results using the GliaSite brachytherapy device as a portion of initial therapy for malignant gliomas. Neuro-Oncology 5(4):349#TA-07. 2003.
  • Burri SH, Landry JC, DeWolfe KD, Godette KD, Machuta SR, Davis LW.  Black and White Patients fare equally well when treated with Post-Lumpectomy Radiotherapy.  International Journal of Radiation Oncology Biology Physics 48:3S 196#169. 2000.
  • Burri SH, Smith RG, Landry JC, Ghavidel S, Davis LW.  Breast    Conservation is an Effective Option in Black, Medically Indigent Patients.  Supplement to Radiology 213(P): 202#447.  November, 1999.
  • Burri SH, Kim CN, Fang G, Davis LW, Bhalla KN. ‘Loop’ Domain Deletional Mutuant of Bcl-XL is as effective as p29
  • Bcl-XL in inhibiting Radiaiton-Induced Cytosolic Accumulation of Cytochrome C, Caspase-3 Activity and Apoptosis.  International Journal of Radiation Oncology Biology Physics 42:1S 137#25. 1998.
  • Burri SH, Liu L, Perkins C, Davis LW, Bhalla KN.  Effect of Bcl-XL or its ‘Loop’ Deletional Mutant Expression on irradiation-induced Cytosolic Cytochrome C, Caspase-3 Activity and Apoptosis.  Proceedings of the American Association for Cancer Research 39: 78#530.  1998.

Invited Lectures

  • “Stereotactic Radiaosurgery – The Ideal Treatment” Levine Cancer Institute Navigator Academy. Charlotte, NC. October 5, 2017.
  • “Levine Cancer Institute : At the forefront of advancing the management of brain metastases”. Wake Forest-Levine Cancer Institute Scientific Symposium. Greensboro, NC. April 7, 2017.
  • “Radiosurgery vs. WBRT: Effects on Cognitive Function.” Radiation therapy Symposium. Charlotte, NC. January 28, 2017 .
  • “The Medical Physicist Value Proposition for Tomorrow and Today” American Academy of Medical Physicists (AAPM) Annual Meeting.  Washington, DC. July 31, 2016.
  • “When to use Radiosurgery for Brain Metastases – Pre- or Post-Operative” Cleveland Clinic 7th Annual International Symposium on Long-Term Control of Metastases to the Brain and Spine.  Las Vegas, NV. October 22, 2016
  • “Controversies: Neo-adjuvant Radiosurgery Followed by Resection of Brain Metastases: Yes or No.” Congress of Neurological Surgeons (CNS) Annual Meeting. Boston, Massachusetts. October 20, 2014.
  • “Clinical Trials: Are they really still necessary in 2014? Rationale, structure, and approach to modern clinical trials.” American Academy of Medical Dosimetrists (AAMD) national webinar. February 17, 2014.
  • “Neo-adjuvant Radiosurgery” Cleveland Clinic 4th Annual International Symposium on Long-Term Control of Metastases to the Brain and Spine.  Las Vegas, NV. November 3, 2013.
  • “Defining Optimal Treatment Strategies for Oligo-Cerebral Metastases” Cone Health Brain Tumor Update. Greensboro, NC. September 3, 2013
  • “Local Therapies for High-Grade Gliomas” Levine Cancer Institute – Roper Brain Tumor Update.  Charleston, SC. November 2, 2012.
  • “Stereotactic Radiosurgery – The Ideal Treatment” Grand Rounds – CaroMont Regional Medical Center. Gastonia, NC. May 22, 2012.
  • “Extra-cranial Stereotactic Radiosurgery” Grand Rounds – Cleveland Regional Medical Center. Shelby, NC. November 30, 2009.
  • “Extra-cranial Stereotactic Radioablation.” American Academy of Medical Dosimetrists Regional Meeting.  Myrtle Beach, SC. April 7, 2006.
  • “Encouraging Early Results Using the GliaSite Brachytherapy Device as a Portion of Initial Therapy for Malignant Gliomas.” 2004 GliaSite Physician Conference. Chicago, Illinois. August 7, 2004.
  • “Clinical Trial Development and Participation.” Society of Radiation Oncology Administrators: Southeast Regional Meeting. Charlotte, NC. June 26, 2004.
  • “Intensity Modulated Radiation Therapy: The Future of Radiation Therapy.” Grand Rounds at Gaston Memorial Hospital. Gastonia, North Carolina. November 26, 2002.
  • “Prostate Cancer and Intensity Modulated Radiation Therapy (IMRT)” Varian Sponsored IMRT Symposium. Charlotte, North Carolina. May 21, 2001.
  • “New Techniques in Radiation Therapy: Stereotactic Radiosurgery, Stereotactic Radiotherapy, and IMRT” William R. Pitts Neuroscience Symposium. Charlotte, North Carolina.  May 1, 2001.
  • “IMRT and Prostate Cancer” South Carolina Oncology Associates Annual Meeting.  Columbia, South Carolina. April 21, 2001.

Protocol Development

  • Co-Principal Investigator: “A Prospective Analysis of Neoadjuvant Radiosurgery and Surgical Resection for the Treatment of 1-3 Cerebral Metastases”, Carolinas Medical Center
  • National Radiation Oncology Study Chair.  American College of Surgeons Oncology Group#Z0300: A Phase III Randomized Trial of the Role of Whole Brain Radiation Therapy in Addition to Radiosurgery in the Management of Patients with One to Three Cerebral Metastases.
  • Radiation Oncology Study Chair for multi-institutional study. Temozolomide as Neoadjuvant and Chemo-radiotherapy Following Resection and GLIADEL® Wafer Placement in Patients With Newly Diagnosed High-grade Glioma.